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PURPOSE. We studied the association between dynamic iris changes and the spectrum of
primary angle closure disease (PACD), using the anterior segment optical coherence
tomography (ASOCT).
METHODS. Eligible primary angle closure (PAC), primary angle closure glaucoma (PACG), age,
and sex comparable primary angle closure suspects (PACS) and normal subjects from the 5-
year follow-up of the Handan Eye Study underwent ASOCT testing in dark and light
conditions. The right eye of each subject was analyzed and biometric parameters including
iris cross-sectional area (IA), lens vault (LV), pupil diameter (PD), and centroid-to-centroid
distance (CCD) were calculated using the Zhongshan Angle Assessment Program.
RESULTS. Totals of 31 PACS, 31 PAC/PACG, and 31 normal eyes were eligible for analysis. Loss
of IA per mm PD increase in the dark compared to light was 0.18 mm in PACS, 0.13 mm in
PAC/PACG, and 0.24 mm in normal (P ¼ 0.015 between groups) groups. Diagnoses of normal
(P ¼ 0.001) and a smaller PD in light (P ¼ 0.003) were statistically significant determinants of
a larger IA loss per mm PD increase in the dark compared to light. Logistic regression analysis
showed that LV (P ¼ 0.002) and IA loss per mm PD increase (P ¼ 0.017) were risk factors for
an occludable angle.
CONCLUSIONS. Significant differences in iris behavior in the dark compared to light in PACS,
PACD, and normal eyes add to the evidence that dynamic iris change has a role in the
pathogenesis of PAC in a rural Chinese population.
Keywords: primary angle closure suspect, primary angle closure disease, iris cross-sectional
area, anterior segment optical coherence tomography, mydriasis
Primary angle closure glaucoma (PACG) is a major cause ofvisual morbidity in Asia, with the largest number of those
affected resident in China.1,2 Traditional known ocular risk
factors of PACG include small eye, shallow central anterior
chamber depth (ACD), short axial length (AL), and a thick and
anteriorly positioned lens.3–5 However, although PACG is more
prevalent among Chinese than Caucasians, the mean ACD and
AL is not significantly different between Chinese, Caucasian, or
black populations.6 This lack of difference suggests that other
risk factors may contribute to the excess burden of PACG
among Asians. Anterior chamber depth and AL do not have
acceptable sensitivity or specificity to screen for angle closure,
and these and other traditional risk factors do not predict
which eyes might have angle closure.7–10 The evidence
suggests that primary angle closure (PAC) is a multifactorial
disease caused by a combination of anatomical and dynamic
components.11–13
The International Society of Geographical and Epidemiolog-
ical Ophthalmology (ISGEO) classification for PAC includes
primary angle closure suspect (PACS), PAC, and PACG.10,14
However, PACS is not a disease state but a group at risk for PAC
and PACG, which represents pathology. Furthermore, because
use of the term ‘‘primary angle closure’’ to refer to PAC and
PACG can lead to confusion, in this report we used the term
primary angle closure disease (PACD) to refer to the disease
states PAC and PACG, and labeled those with only the risk factor
of occludable angles as PACS.15 The three terms PACS, PAC, and
PACG share the common characteristic of an occludable angle,
defined as nonvisibility of posterior trabecular meshwork for at
least 1808.9
Recent reports suggest that the main dynamic risk factors
involved in PACD include changes in the iris and choroid.16–26
As far as the iris is concerned, it has been hypothesized that
since iris loses water with pupil dilation (because of the high
fluid content of its stroma and the capacity for fluid
movement), irides with more compact or water-retentive
stroma (poor fluid conductivity) may be a dynamic factor that
could predispose some anatomically susceptible eyes to PAC.16
Using anterior segment optical coherence tomography
(ASOCT), PACS and PAC eyes of subjects of Caucasian ancestry
showed a smaller loss of iris cross-sectional area (IA) following
physiologic/pharmacologic dilation compared to those with
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open angles.16 Similar findings have been reported in South
Indians: IA and iris volume (IV) decreased with pupillary
dilatation in normal and PAC eyes with the loss of IV lower in
PAC.17 In a French report, IVs in fellow eyes of patients with
acute angle closure (AAC) increased following physiologic and
pharmacologic mydriasis.19,20 A study from Singapore also
reported an increased IV following physiologic dilation of the
fellow eyes of AAC.21 The increase in IV is paradoxical and
Quigley et al.27 have shown that increased IV is an artifact
caused by an increase of centroid-to-centroid distance (CCD)
used in the formula to calculate IV from IA.27
Using data from the Handan Eye Study (HES), we have
reported previously that PACS and normal eyes respond
differently to physiologic and pharmacologic pupillary dilation,
with the former showing a smaller reduction in IA and IV.18
However, the formula used in that study suffered from the
deficiency raised by Quigley et al.27 and we now elect to use
IA, rather than IV to represent iris dynamic change. In another
study, we investigated the IA change after physiologic and
pharmacologic mydriasis in PACS/PAC/PACG subjects with
different dominant mechanisms for angle closure of the same
population and reported that the smallest decrease of IA
occurred in eyes with pupillary block as the dominant
mechanism.15
The objective of this study was 3-fold: (1) quantify changes
and differences in IA in the dark compared to light in normal,
PACS, and PAC/PACG subjects; (2) study the association of such
changes with demographic factors and previously reported
ocular biometric measurements; and (3) investigate the
possible risk factors (anatomical and dynamic) for PAC.
METHODS
Subjects and Ophthalmic Examination
This observational, cross-sectional study was conducted on a
sample of PACS, PAC/PACG, and normal subjects selected from
the 5-year follow-up of the HES; the study has been described
in detail previously.8,15 Consecutive subjects aged ‡40 years
old who participated in the follow-up examination between
September 2012 and May 2013 and had an occludable angle
(posterior trabecular meshwork not visible for at least 1808 on
gonioscopy) with peripheral anterior synechiae (PAS) and/or
increased IOP, with or without glaucomatous optic neuropathy
(GON), were included in the PAC/PACG group.10,14 An equal
number of age and sex comparable PACS and normal subjects
were selected from a previous study, which was also
conducted on the 5-year follow-up cohort of the HES.8 Primary
angle closure suspects (PACS) was defined as posterior
trabecular meshwork not visible for at least 1808 on static
gonioscopy without PAS on indentation/manipulation, IOP 
21 mm Hg, healthy optic nerves, and normal visual fields.10,14
Normal was defined as IOP  21 mm Hg with open angles,
healthy optic nerves, and normal visual fields, no previous
surgery, and no family history of glaucoma.
Subjects with an axial length shorter than 19 mm or longer
than 25 mm, previous intraocular surgery other than filtering
surgery, previous eye injury, or corneal disorders preventing
anterior chamber assessment, those on topical or systemic
medication that could affect the iris or angle configuration,
those who had suffered an episode of AAC or undergone laser
iridoplasty, as well as subjects with a diagnosis of diabetic
retinopathy or other fundus diseases were excluded.15,18
A comprehensive ophthalmic examination including pre-
senting (PVA) and best corrected LogMAR visual acuity (BCVA),
objective and subjective refraction, slit-lamp biomicroscopy,
visual field examination, applanation tonometry, gonioscopy, A-
scan ultrasound biometry, and fundus examination was
performed on all participants.15,18 A KR-8800 auto keratore-
fractometer (Topcon, Tokyo, Japan) was used to measure
refraction of subjects, while the 24-2 Swedish Interactive
Testing Algorithm (SITA) standard program on a visual field
analyzer (Humphrey Visual Field Analyzer 740i or 750i; Carl
Zeiss, Jena, Germany) was used for visual field testing.
OcuScan RxP (Alcon, Inc., Fort Worth, TX, USA) was used
for measurement of central corneal thickness (CCT), ACD, lens
thickness (LT) and AL.15,18
The study adhered to the Declaration of Helsinki and was
approved by the ethics committee of the Beijing Tongren
Hospital. All subjects provided verbal and written informed
consent.
ASOCT Image Acquisition
An ASOCT (Visante, Carl Zeiss Meditec, Inc., Dublin, CA,
USA), a noncontact optical coherence tomographic system
using 1310 nm wavelength light to capture high resolution
cross-sectional images of ocular anterior segment, was used to
image each eye of all subjects, first in the dark (approximately
3 lux, to induce physiologic mydriasis) and then after 3
minutes of exposure to approximately 200 lux of light.28,29
The dark measurements were made after 3 minutes of dark
adaptation.
All images were obtained in the ‘‘anterior segment
quadrant’’ mode at 0 to 180, 45 to 225, 90 to 270, and 1358
to 3158 meridians. The operator gently retracted the upper and
lower lids as needed for a better vertical image acquisition,
taking care to avoid inadvertent pressure on the globe. If
scleral spur visibility was poor, the imaging was repeated and
the best set of images selected.15,18 As a small change in pupil
diameter (PD) would not contribute to, or even mask
information, eyes with a PD increase of less than 0.5 mm after
physiologic mydriasis were excluded.27
Image Analysis
The Zhongshan Angle Assessment Program (ZAAP, Guangzhou,
China) was used to measure and calculate the angle and
anterior chamber configuration parameters. These included
angle opening distance at 500 lm (AOD500), trabecular-iris
space area at 500 lm (TISA500), angle recess area at 750 lm
(ARA750), anterior chamber area (ACA), anterior chamber
volume (ACV), and anterior chamber width (ACW); iris-related
parameters, including iris thickness at 750 lm (IT750), iris
curvature (IC) and IA, and lens vault (LV), CCD, and PD (see
Fig.). The scleral spur was located manually on each side of the
image.30
The AOD500 is the distance from the corneal endothelium
to the iris surface as determined from a perpendicular to a line
drawn at 500 lm from the scleral spur.31 The TISA500 is the
area bounded anteriorly by the AOD500, posteriorly by a line
drawn from the scleral spur perpendicular to the plane of the
inner scleral wall to the iris, superiorly by the inner
corneoscleral wall and inferiorly by the iris surface.32 The
ARA750 is the area bordered by the anterior iris surface,
corneal endothelium, and a line perpendicular to the corneal
endothelium drawn to the iris surface from a point at 750 lm
anterior to scleral spur.33 The ACW is measured as the distance
between the left and right scleral spur.34 The ACA is defined as
the cross-sectional area of the anterior segment bounded by
the corneal endothelium, anterior surface of the iris, and
anterior surface of the lens (within the pupil), and ACV is
calculated by rotating the ACA 3608 around the vertical axis
which is through the midpoint (center) of the ACA.35
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The IT750 is defined as the shortest distance between
designated locations (at 750 lm from the scleral spur) at the
anterior and posterior iris surface.34 Iris curvature is
determined by measuring the maximum distance between
the posterior iris surface and a line from the iris root to the
first point of contact between the iris and lens.34 Iris cross-
sectional area was defined as the cross-sectional area of the
nasal and temporal sides.36 The changes in ASOCT parameters
were measured going from dark to light. To make the results
easier to analyze and understand, the larger values minus the
smaller values of each parameter were chosen to present the
changes.
Lens vault is the perpendicular distance between the
anterior pole of the lens and a horizontal line joining the two
scleral spurs of the same cross-sectional image.37 Centroid-to-
centroid distance is the distance between the centers of the
nasal and temporal iris masses.27 Pupil diameter was automat-
ically measured as the distance between the pupillary tips of
the iris on both sides on the cross-sectional images.34
All images were analyzed by a single experienced observer
(ZY). Each value represented the average of measurements
from eight iris cross-sections as obtained from ASOCT scans.
Statistical Analysis
Data from the right eye were used for analysis. Variables
demonstrating a normal distribution are presented as mean
(SD), while variables failing to achieve a normal distribution
are presented as median (percentiles). Analysis of variance,
nonparametric tests, and the v2 test were used to compare
differences between the normal, PACS, and PAC/PACG
groups.
Multivariable linear regression was conducted with IA loss
per millimeter (mm) PD increase as the dependent/predicted
variable, and age, sex, spherical equivalent (SE), CCT, ACD, LT,
AL, PD in light, PD in dark, CCD in light, CCD in dark, CCD
change, and diagnosis (PACS versus normal, PAC/PACG versus
normal) as independent/predictor variables.
Logistic regression models were used to determine the odds
ratios (ORs) and 95% confidence intervals (CI) for putative risk
factors associated with occludable angle (for both PACS and
PAC/PACG), using a backward procedure in multivariable
logistic regression analysis for all variables with P < 0.05 in a
univariable analysis. Since age and sex were comparable
between three groups, parameters including ACD, LT, AL,
IT750 in light, IT750 in dark, IC in light, IC in dark, LV in light,
LV in dark, and IA loss per mm PD increase were assessed as
possible independent variables.
All analyses were performed using SPSS statistical software
version 17.0 (SPSS, Inc., Chicago, IL, USA) for Windows. P
values less than 0.05 were considered significant.
RESULTS
Subjects Characteristics
There were 45 PAC/PACG subjects attending the 5-year HES
follow-up during September 2012 to May 2013 eligible for
inclusion. A total of 14 PAC/PACG eyes was excluded: five eyes
(11.1%) due to poor image quality or inability to accurately
identify the scleral spur and nine eyes with pupil diameter
change less than 0.5 mm in the dark compared to light. There
were no statistically significant differences in demographic or
ocular features between the included and excluded PAC/PACG
eyes/patients. A total of 93 eyes (31 PAC/PACG, 31 PACS, and
31 normal eyes) was available for final analysis.
Table 1 shows the demographic characteristics and ocular
biometric data of subjects in the PACS, PAC/PACG, and normal
groups. Reliable visual field examination results were
available for 21 normal, 24 PACS, and 25 PAC/PACG subjects.
There was no significant difference in age, sex, PVA, BCVA,
SE, IOP, CCT, and LT among the three groups. There was a
significant difference in ACD (P ¼ 0.014), AL (P ¼ 0.005),
mean deviation (MD; P ¼ 0.036), and pattern standard
deviation (PSD; P ¼ 0.021) among the three groups with the
deepest ACD, longest AL, highest MD, and lowest PSD in the
normal group.
The mean values and the absolute and relative changes
when going from dark to light for ASOCT parameters in
PACS, PAC/PACG, and normal groups along with the
TABLE 1. Demographic Data and Ocular Biometric Measurements in Normal, PACS, and PAC/PACG Subjects
Parameter
Normal
Subjects,
n ¼ 31
PACS
Subjects,
n ¼ 31
PAC/PACG
Subjects,
n ¼ 31 P Value
P Value,
Normal
vs. PACS
P Value,
Normal vs.
PAC/PACG
P Value,
PACS vs.
PAC/PACG
Age (SD), y 63.3 (8.5) 63.8 (6.5) 64.0 (6.4) 0.901*
Male (%) 14 (45.2) 14 (45.2) 14 (45.2) 1.000†
Female (%) 17 (54.8) 17 (54.8) 17 (54.8)
PVA (IR) 0.20 (0.14, 0.40) 0.30 (0.18, 0.50) 0.28 (0.12, 0.40) 0.361*
BCVA (IR) 0.00 (0.00, 0.20) 0.10 (0.00, 0.30) 0.00 (0.00, 0.20) 0.478‡
SE (IR), diopter 0.00 (0.00, 0.75) 0.63 (0.00, 1.31) 0.44 (0.00, 1.13) 0.192‡
IOP (SD), mm Hg 12.3 (2.6) 12.0 (2.4) 13.8 (5.3) 0.120‡
CCT (SD), mm 534 (23) 536 (32) 540 (28) 0.737*
Central ACD
(SD), mm 2.75 (0.26) 2.52 (0.27) 2.65 (0.38) 0.014* 0.010§ 0.426§ 0.203§
LT (SD), mm 4.71 (0.50) 4.89 (0.39) 4.70 (0.56) 0.251*
AL (SD), mm 22.87 (0.90) 22.19 (0.78) 22.53 (0.67) 0.005* 0.003§ 0.209§ 0.219§
MD 3.99 (4.48) (n ¼ 21) 4.12 (2.68) (n ¼ 24) 7.01 (5.69) (n ¼ 25) 0.036* 1.000j j 0.078j j 0.077j j
PSD 3.22 (2.42) (n ¼ 21) 3.74 (2.65) (n ¼ 24) 5.31 (2.65) (n ¼ 25) 0.021* 1.000j j 0.026j j 0.109j j
IR, interquartile range.
* 1-way ANOVA.
† v2 test.
‡ Kruskal-Wallis test.
§ Tukey’s Honestly Significant Difference (HSD).
j j Bonferroni test.
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differences among the three groups are summarized in
Tables 2 and 3.
In the light condition, a significant difference in AOD500,
TISA500, IC, ARA750, ACD, ACW, ACA, ACV, and LV was found
among the three groups (P < 0.05). In the dark condition,
AOD500, TISA500, ARA750, ACD, ACA, ACV, and LV showed
significant differences among the three groups (P < 0.05).
IA Measurements
Mean IAs, CCDs, and PDs from eyes of the three groups
measured in light and dark are summarized in Table 4. A
significant difference in IA in dark condition (P ¼ 0.006)
existed among the three groups with the largest IA in the PAC/
PACG group. There was no significant difference in CCD and
TABLE 2. Anterior Chamber, Angle, and Lens Parameters Measured by ASOCT in Light and Dark Conditions
Conditions Parameter
Normal
Subjects,
n ¼ 31
PACS
Subjects,
n ¼ 31
PAC/PACG
Subjects,
n ¼ 31 P Value
P Value,
Normal
vs. PACS†
P Value,
Normal vs.
PAC/PACG†
P Value,
PACS vs.
PAC/PACG†
Light AOD500; L (SD), mm 0.338 (0.084) 0.248 (0.078) 0.194 (0.083) <0.001 <0.001 <0.001 0.029
TISA500; L (SD), mm2 0.140 (0.035) 0.103 (0.032) 0.068 (0.030) <0.001 <0.001 <0.001 <0.001
ARA750; L (SD), mm2 0.357 (0.110) 0.269 (0.093) 0.176 (0.087) <0.001 0.002 <0.001 0.001
ACW; L (SD), mm 11.10 (0.30) 10.88 (0.36) 10.90 (0.46) 0.045 0.067 0.090 0.991
ACA; L (SD), mm2 17.97 (2.31) 15.96 (2.04) 14.69 (2.61) <0.001 0.003 <0.001 0.089
ACV; L (SD), mm3 72.71 (12.21) 62.03 (10.51) 55.69 (13.61) <0.001 0.002 <0.001 0.106
IT750; L (SD), mm 0.46 (0.07) 0.47 (0.06) 0.47 (0.06) 0.630
IC; L (SD), mm 0.23 (0.06) 0.26 (0.06) 0.19 (0.12) 0.005 0.541 0.077 0.004
LV; L (SD), lm 286.8 (157.6) 402.5 (129.9) 545.1 (232.3) <0.001 0.033 <0.001 0.006
Dark AOD500; D (SD), mm 0.293 (0.082) 0.203 (0.074) 0.107 (0.077) <0.001 <0.001 <0.001 <0.001
TISA500; D (SD), mm2 0.117 (0.031) 0.079 (0.030) 0.038 (0.023) <0.001 <0.001 <0.001 <0.001
ARA750; D (SD), mm2 0.299 (0.096) 0.207 (0.095) 0.108 (0.080) <0.001 <0.001 <0.001 <0.001
ACW; D (SD), mm 11.14 (0.29) 10.99 (0.42) 11.10 (0.42) 0.271
ACA; D (SD), mm2 18.52 (2.28) 16.51 (2.15) 15.12 (2.61) <0.001 0.003 <0.001 0.057
ACV; D (SD), mm3 74.85 (12.18) 64.53 (11.56) 57.69 (13.47) <0.001 0.004 <0.001 0.083
IT750; D (SD), mm 0.49 (0.06) 0.50 (0.06) 0.52 (0.06) 0.164
IC; D (SD), mm 0.24 (0.06) 0.26 (0.08) 0.23 (0.10) 0.248
LV; D (SD), lm 327.8 (163.4) 461.1 (173.7) 662.2 (225.3) <0.001 0.018 <0.001 <0.001
L, light; D, dark.
* 1-way ANOVA.
† Tukey’s Honestly Significant Difference (HSD).
TABLE 3. Anterior Segment Optical Coherence Tomography: Changes in Anterior Chamber, Angle, and Lens Parameters from Dark to Light
Parameter
Normal
Subjects,
n ¼ 31
PACS
Subjects,
n ¼ 31
PAC/PACG
Subjects,
n ¼ 31 P Value
P Value,
Normal
vs. PACS
P Value,
Normal vs.
PAC/PACG
P Value,
PACS vs.
PAC/PACG
AOD500; AC (SD), mm 0.045 (0.060) 0.045 (0.069) 0.087 (0.064) 0.017* 1.000† 0.034† 0.034†
TISA500; AC (SD), mm2 0.024 (0.023) 0.024 (0.025) 0.030 (0.023) 0.437*
ARA750; AC (SD), mm2 0.059 (0.067) 0.062 (0.074) 0.068 (0.075) 0.861*
ACW; AC (SD), mm 0.04 (0.15) 0.10 (0.20) 0.21 (0.21) 0.003* 0.374† 0.002† 0.091†
ACA; AC (SD), mm2 0.55 (0.35) 0.56 (0.42) 0.43 (0.72) 0.537*
ACV; AC (SD), mm3 2.14 (2.65) 2.50 (3.17) 2.00 (3.22) 0.801*
IT750; AC (SD), mm 0.03 (0.04) 0.03 (0.03) 0.05 (0.05) 0.313*
IC; AC (SD), mm 0.002 (0.061) 0.002 (0.081) 0.040 (0.076) 0.067*
LV; AC (SD), lm 41.0 (77.8) 58.7 (114.5) 117.1 (140.0) 0.026* 0.814† 0.027† 0.113†
AOD500; RC (SD) 0.144 (0.301) 0.144 (0.301) 0.470 (0.290) <0.001* 0.967† <0.001† <0.001†
TISA500; RC (SD) 0.198 (0.295) 0.198 (0.295) 0.418 (0.312) <0.001* 0.838† 0.001† 0.004†
ARA750; RC (SD) 0.204 (0.323) 0.204 (0.323) 0.350 (0.414) 0.044* 0.808† 0.042† 0.166†
ACW; RC (SD) 0.01 (0.02) 0.01 (0.02) 0.02 (0.02) 0.003* 0.385† 0.002† 0.075†
ACA; RC (SD) 0.04 (0.02) 0.04 (0.02) 0.03 (0.05) 0.860*
ACV; RC (SD) 0.04 (0.05) 0.04 (0.05) 0.04 (0.06) 0.693*
IT750; RC (SD) 0.07 (0.08) 0.07 (0.08) 0.11 (0.12) 0.329*
IC; RC (IR) 0.04 (0.15, 0.09) 0.04 (0.15, 0.09) 0.17 (0.06, 0.48) 0.042‡ 0.751§ 0.039§ 0.024§
LV; RC (IR) 0.16 (0.01, 0.39) 0.16 (0.01, 0.39) 0.21 (0.05, 0.45) 0.581‡
Changes in AOD500, TISA500, and ARA750: values measured in the light minus values measured in the dark. Changes in ACW, ACA, ACV, IT750,
IC, and LV: values measured in the dark minus values measured in the light. AC, absolute change; RC, relative change.
* 1-way ANOVA.
† Tukey’s Honestly Significant Difference (HSD).
‡ Kruskal-Wallis test.
§ Mann-Whitney U test (<0.05/3¼ 0.017 ¼ significant different).
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PD among the three groups under either light or dark
conditions.
A summary of changes in IA, IA loss per mm PD increase, PD
change, CCD change, and CCD increase per mm PD increase
also is presented in Table 4. Iris cross-sectional area decreased
in the dark compared to light in all eyes. Significant differences
in the IA loss per mm PD increase in dark compared to light
were observed among the three groups (P ¼ 0.015); the
smallest IA loss occurred in the PAC/PACG group. The CCD
increase per mm PD increase (P¼ 0.005) was also significantly
different among the three groups, with the largest increase in
the PAC/PACG group. Tukey’s HSD corrected comparisons
showed significant differences in the IA loss per mm PD
increase (P¼0.011) and CCD increase per mm PD increase (P¼
0.004) between the normal and PAC/PACG groups.
Regression Analysis
Results of multivariable linear regression analysis of IA loss per
mm PD increase are shown in Table 5. Two variables, CCD in
light and PD in dark, were excluded because of collinearity
with other independent variables. Diagnoses of normal eyes (P
¼ 0.001) and a smaller PD in light (P¼ 0.003) were significant
determinants of a larger IA loss per mm PD increase.
The results of the logistic regression analysis are presented
in Table 6. A univariable analysis showed that ACD (P¼ 0.025),
AL (P¼ 0.007), LV in light (P < 0.001), LV in dark (P < 0.001),
and IA loss per mm PD increase (P ¼ 0.027) were associated
with an occludable angle. The multivariable logistic regression
analysis included all parameters for which the P value of the
association with an occludable angle was <0.05 in the
univariable analysis. However, we could not include LV in
light and LV in dark, since they were related. Accordingly, ACD,
AL, LV in light, and IA loss per mm PD increase were included
in the multivariable logistic regression analysis: risk factors
independently associated with an occludable angle were
greater LV (P ¼ 0.002; OR, 1.006; 95% CI, 1.002–1.009) and
less IA loss per mm PD increase (P¼ 0.017; OR, 0.015; 95% CI,
<0.001–0.473).
Comparison Between Treated and Untreated PAC/
PACG Subjects (Eyes)
Eight treated PAC/PACG eyes, three posttrabeculectomy and
five with a laser peripheral iridotomy (LPI), were included in
this study. There were no significant differences in age, sex,
PVA, BVAR, SE, IOP, ACD, LT, LV (in light and dark), IA change,
PD change, IA loss per mm PD increase, or CCD change
between treated and untreated PAC/PACG eyes (P ¼ 0.585,
1.000, 0.567, 0.256, 0.587, 0.463, 0.432, 0.517, 0.139, 0.325,
0.893, 0.315, 0.560, and 0.442, respectively). Treated eyes had
longer AL, larger AOD500 in light, larger TISA500, ARA750,
ACV, and smaller IC in light and dark (P¼ 0.030, 0.026, 0.007,
0.001, 0.048, 0.003, 0.012, 0.001, 0.042, and 0.001, respec-
tively), compared to untreated ones (Table 7).
DISCUSSION
The spectrum of primary angle closure ‘‘disease’’ includes
three different stages, PACS, PAC, and PACG.10,14 Primary angle
closure subjects are those at risk for PAC and PACG. The
presence of raised IOP (>21 mm Hg) and/or PAS in a PACS is
termed PAC, and the presence of GON/visual field loss with
PAC is considered PACG.
TABLE 4. Anterior Segment Optical Coherence Tomography Data for IA, CCD, PD in Dark and Light Conditions
Parameter
Normal
Subjects,
n ¼ 31
PACS
Subjects,
n ¼ 31
PAC/PACG
Subjects,
n ¼ 31 P Value
P Value,
Normal
vs. PACS†
P Value,
Normal vs.
PAC/PACG†
P Value,
PACS vs.
PAC/PACG†
IA; L (SD), mm2 3.01 (0.36) 2.87 (0.26) 3.08 (0.40) 0.061
CCD; L (SD), mm 7.55 (0.39) 7.50 (0.33) 7.42 (0.49) 0.431
PD; L (SD), mm 3.82 (0.58) 3.84 (0.46) 3.69 (0.72) 0.559
IA; D (SD), mm2 2.77 (0.35) 2.70 (0.29) 2.95 (0.27) 0.006 0.956 0.008 0.003
CCD; D (SD), mm 8.07 (0.39) 8.03 (0.36) 8.02 (0.47) 0.874
PD; D (SD), mm 4.83 (0.56) 4.79 (0.49) 4.65 (0.66) 0.437
IA change (SD), mm2 0.24 (0.16) 0.18 (0.15) 0.13 (0.26) 0.094
IA loss per mm PD increase (SD), mm 0.24 (0.16) 0.18 (0.16) 0.08 (0.29) 0.015 0.492 0.011 0.174
PD change (SD), mm 1.01 (0.35) 0.95 (0.31) 0.96 (0.43) 0.792
CCD change (SD), mm 0.52 (0.20) 0.53 (0.22) 0.60 (0.25) 0.333
CCD increase per mm PD increase (SD) 0.51 (0.08) 0.56 (0.19) 0.64 (0.17) 0.005 0.475 0.004 0.087
Changes in IA and IA loss per mm PD increase: values measured in the light minus values measured in the dark. Changes in PD, CCD, and CCD
increase per mm PD increase: values measured in the dark minus values measured in the light.
* 1-way ANOVA.
† Tukey’s Honestly Significant Difference (HSD).
TABLE 5. Factors Associated With IA Loss per mm PD Increase
Variable b P Value Direction
Age, y 0.112 0.265 –
Sex 0.127 0.203 –
SE, D 0.129 0.197 –
CCT, mm 0.173 0.082 –
ACD, mm 0.109 0.277 –
LT, mm 0.130 0.194 –
AL, mm 0.010 0.922 –
PACS subjects
vs. normal 0.117 0.302 –
PAC/PACG subjects
vs. normal
0.337 0.001 Normal eyes had
more IA loss per
mm PD increase
PD; L, mm 0.308 0.003 Eyes with smaller
PD (L) had more
IA loss per mm
PD increase
CCD; D, mm 0.010 0.942 –
CCD change;
L to D, mm 0.018 0.861 –
Change in CCD: values measured in the dark minus values
measured in the light.
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Population-based, prospective cohort studies have shown
that a minority of PACS cases develop PAC/PACG. In south
Indians aged 35 to 65 years, 22% of PACS cases progressed to
PAC in 5 years (4.4% per year).9 Of a cohort of Greenland
Eskimos aged 30 and above with an occludable angle, 35%
developed PACG over 10 years (3.5% per year).38 Ye et al.39
reported that over a follow-up period of 6 years, 4.1% of
subjects aged 40 and older with an ACD 2.0 mm or
peripheral anterior chamber depth 1/4 corneal thickness or
1/4 iris light band ratio on the nasal under flash light
examination, suffered PACG.39
Evidence is accumulating that iris dynamic changes along
with anatomical factors, may contribute to the progres-
sion.16,17,19–21 Primary angle closure disease is a multifactorial
disease for which the individual factors can be considered in the
framework of a sufficient component causal model.13 Our
previous study of PACS and normal subjects suggested that the
dynamic behavior of the iris is likely to be one of the component
causes in sufficient component causal models for PAC/PACG.18
In this study, IA loss from the light to dark condition was
used as the parameter for dynamic iris change. Iris cross-
sectional area decreased in PACS, PAC/PACG, and normal eyes
after physiologic dilation. Statistically significant differences
existed among the three groups, with the smallest IA loss in the
PAC/PACG group. Multivariable regression showed that normal
eyes had more IA loss per mm PD increase, compared to PAC/
PACG eyes. All these findings provide further support for the
hypothesis that a diminished tendency to lose IA with dilation
contributed to PAC.16
An interesting finding is the significant difference in the
CCD increase per mm PD increase between PACS, PAC/PACG,
and normal eyes, with the largest CCD increase per mm PD
increase occurring in PAC/PACG eyes. The ratio of CCD
increase to pupil dilation can be considered a measure of iris
area redistribution peripherally.27 Our results showed that
following physiologic dilation of the pupil, PAC/PACG eyes had
more peripheral redistribution of IA when compared to normal
eyes; in eyes at risk this likely contributes to the narrowing or
closing of the anterior chamber angle.
Equally interesting are the results of logistic regression
analysis, which showed that only greater LV and less IA per mm
PD increase were associated with occludable angles while
traditionally described risk factors, including ACD, LT, and AL,
were not significant. The A-scan ultrasound biometry results
showed that PACS eyes had the smallest central ACD, largest LT,
and smallest AL, compared to normal and PAC/PACG eyes, with
significant differences in central ACD and AL. While it is possible
that the small numbers may have been responsible for failure to
achieve significance for some risk factors, we feel this is further
TABLE 6. Univariable and Multivariable Logistic Regression of Risk Factors for Occludable Angle
Variable
Univariable Multivariable
OR for Occludable Angle (95% CI) P Value OR for Occludable Angle (95% CI) P Value
ACD, mm 0.180 (0.040, 0.810) 0.025 – 0.594
LT, mm 1.424 (0.595, 3.406) 0.427 – –
AL, mm 0.452 (0.254, 0.804) 0.007 0.553 (0.281, 1.090) 0.087
IT750; L, mm 29.763 (0.031, 28658.372) 0.333 – –
IC; L, mm 0.205 (0.001, 28.579) 0.529 – –
LV; L, lm 1.007 (1.003, 1.010) <0.001 1.006 (1.002, 1.009) 0.002
IT750; D, mm 627.734 (0.294, 1341926.676) 0.100 – –
IC; D, mm 2.939 (0.014, 631.126) 0.694 – –
LV; D, lm 1.007 (1.003, 1.010) <0.001 – –
IA loss per mm PD increase, mm 0.046 (0.003, 0.702) 0.027 0.015 (<0.001, 0.473) 0.017
Changes in IA loss per mm PD increase: values measured in the light minus values measured in the dark.
TABLE 7. Comparison Between Treated and Untreated PAC/PACG
Subjects
Parameter
Treated
PAC/PACG
Subjects, n ¼ 8
Untreated
PAC/PACG
Subjects, n ¼ 23 P Value
Age (SD), y 65.1 (3.5) 63.7 (7.2) 0.585*
Male (%) 4 (50.0) 14 (45.2) 1.000†
Female (%) 4 (50.0) 17 (54.8)
PVA (SD) 0.30 (0.22) 0.25 (0.19) 0.567*
BCVA (IR) 0.10 (0.00, 0.28) 0.00 (0.00, 0.20) 0.256‡
SE (SD), diopter 0.40 (0.82) 0.63 (0.95) 0.587*
IOP (SD), mm Hg 12.6 (2.5) 14.2 (5.9) 0.463*
Central ACD (SD),
mm 2.75 (0.26) 2.62 (0.41) 0.432*
LT (SD), mm 4.59 (0.77) 4.74 (0.49) 0.517*
AL (SD), mm 22.96 (0.53) 22.37 (0.66) 0.030*
AOD500 (SD); L,
mm 0.250 (0.076) 0.175 (0.078) 0.026*
TISA500 (SD); L,
mm2 0.092 (0.032) 0.060 (0.025) 0.007*
ARA750 (SD); L,
mm2 0.259 (0.097) 0.148 (0.063) 0.001*
ACV (SD); L, mm3 63.80 (13.36) 52.86 (12.78) 0.048*
IC (SD); L, mm 0.08 (0.05) 0.22 (0.12) 0.003*
LV (SD); L, lm 650.3 (212.9) 508.5 (231.8) 0.139*
AOD500 (SD); D,
mm 0.151 (0.074) 0.092 (0.073) 0.058*
TISA500 (SD); D,
mm2 0.055 (0.029) 0.032 (0.018) 0.012*
ARA750 (SD); D,
mm2 0.181 (0.116) 0.082 (0.043) 0.001*
ACV (SD); D, mm3 65.93 (14.78) 54.82 (12.02) 0.042*
IC (SD); D, mm 0.14 (0.07) 0.26 (0.08) 0.001*
LV (SD); D, lm 730.8 (156.7) 638.3 (243.1) 0.325*
IA change (SD),
mm2 0.14 (0.39) 0.13 (0.21) 0.893*
PD change (SD),
mm 1.09 (0.49) 0.91 (0.41) 0.315*
IA loss per mm PD
Increase (SD) 0.03 (0.42) 0.10 (0.24) 0.560*
CCD change (SD),
mm 0.66 (0.21) 0.58 (0.27) 0.442*
Changes in IA and IA loss per mm PD increase: values measured in
the light minus values measured in the dark. Change in PD and CCD
change: values measured in the dark minus values measured in the
light.
* Independent t-test.
† v2 test.
‡ Mann-Whitney U test.
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evidence that risk factors other than those traditionally
considered responsible contribute to the pathogenesis of PACD.
Lens vault is a recently described parameter that represents
the height of the lens anterior to the scleral spur plane, and has
been reported to be a significant predictor of angle closure
disease.11 Our study supported that finding. It would seem that
a larger LV predisposes the eye to angle closure through at least
two mechanisms. The larger area of the crystalline lens
protruding anteriorly is expected to increase pupillary block
via increased iridolenticular contact, while the greater the LV,
the more the iris may be pushed anteriorly and aggravate angle
narrowing.40,41 However, while achieving statistical signifi-
cance, the OR for LV (OR, 1.006; 95% CI, 1.002–1.009) was
marginal and less impressive than that for IA loss per mm PD
increase (OR 0.015; 95% CI, <0.001–0.473).
As far as IA loss per mm PD increase is concerned, the
smaller the loss of iris area the narrower the angle becomes
with dilatation. We suggest that what may matter most in angle
closure is the relative location of the lens and the changes in
the angle as the pupil dilates; both are explained by the two
factors that we found to be significant. It seems logical that
pupillary block (through any mechanism, including LV) and iris
changes as the pupil dilates are keys to angle closure and this
fits our understanding of a sufficient component causal model
for PAC/PACG.12,13
The MD and PSD of visual fields were different between
normal, PACS, and PACD. Advanced field defects can cause a
change in pupillary reaction and could possibly affect the
behavior of the iris.42,43 However, it seems more plausible that
dynamic iris changes lead to changes in IOP that then are
followed by damage that manifests as visual field defects.
Iridotomy and trabeculectomy may change the dynamic
response of iris during physiologic pupil dilation, particularly
by eliminating pupillary block as well as a decrease in iris
tension decreasing iris mobility; this may represent a potential
bias in our study.19 According to the reasoning for two major
factors being involved as detailed above, it also is possible that
inclusion of cases where pupillary block was eliminated may
have led to the lower effect size for lens vault. While no
significant difference was found in IA loss between treated and
untreated eyes following physiologic mydriasis the numbers
are too few to comment on the effect of iridotomy/
trabeculectomy on iris dynamic changes.
The results of our study should be interpreted with its
several limitations in mind. As all patients were of Chinese
descent, the results may not be entirely applicable to other
ethnic groups. The number of subjects included in this study is
relatively small. While a larger sample size is desirable, the
findings can be interpreted in the light of prior knowledge and
biological plausibility: our results add to the existing evidence
about lens vault and iris dynamic changes. As discussed above,
the inclusion of treated eyes could have introduced a bias. The
numbers were small but there were no differences between
treated and untreated eyes, and we believe that such a bias
would be expected to be toward the null. We grouped and
analyzed PAC and PACG together as it is optic neuropathy that
determines that classification and there is as yet no evidence
for a difference in iris behavior or lens vault between PAC and
PACG. Finally, as this was a cross-sectional study, a cause and
effect relationship cannot be proven; the actual clinical risk
factors for PACS and PAC/PACG remain to be confirmed in
prospective, longitudinal studies.
In summary, this study provides further data on iris dynamic
changes in PACS, PAC/PACG, and normal eyes as well as other
risk factors associated with PACD. Our data suggested that the
lens vault and iris dynamic change have a role in the
pathogenesis of PAC, as demonstrated in a rural Chinese
population. These findings emphasized the role of lens vault
along with other factors in producing pupillary block and the
need to evaluate the iris as a dynamic risk factor in PAC. We
also highlight the need for longitudinal research into the role of
iris dynamic changes and other risk factors in the pathogenesis
of PAC and their possible use in predicting disease.
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